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Abstract
Background:  Studies in adult intensive care have highlighted the importance of insulin and
improved glucose control on survival, with 32% reduction in mortality, 22% reduction in intensive
care stay and halving of the incidence of bacteraemia. Very low birth weight infants requiring
intensive care also have relative insulin deficiency often leading to hyperglycaemia during the first
week of life. The physiological influences on insulin secretion and sensitivity, and the potential
importance of glucose control at this time are not well established. However there is increasing
evidence that the early postnatal period is critical for pancreatic development. At this time a
complex set of signals appears to influence pancreatic development and β cell survival. This has
implications both in terms of acute glucose control but also relative insulin deficiency is likely to
play a role in poor postnatal growth, which has been associated with later motor and cognitive
impairment, and fewer β cells are linked to risk of type 2 diabetes later in life.
Methods: A multi-centre, randomised controlled trial of early insulin replacement in very low
birth weight babies (VLBW, birth weight < 1500 g). 500 infants will be recruited from 10 centres
in the UK and Europe. Babies will be randomised to receive a continuous insulin infusion (0.05
units/kg/h) or to receive standard neonatal care from the first day of life and for the next 7 days. If
blood glucose (BG) levels fall infants will receive 20% dextrose titrated to maintain normoglycaemia
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(4–8 mmol/l). If BG is consistently above 10 mmol/l babies will receive standard treatment with
additional insulin infusion. The primary end point will be mortality on or before expected date of
delivery, secondary end points will be markers of morbidity and include episodes of sepsis, severity
of retinopathy, chronic lung disease and growth.
Trial Registration: Current Controlled Trials ISRCTN78428828. EUDRACT Number 2004-
002170-34
Background
Perinatal survival in very low birth weight infants (less
than 1.5 kg) has increased markedly over the last twenty
years with improvements in neonatal intensive care [1].
However mortality rates are as high as 20% in those born
less than 1 kg, death may be related to either infection or
necrotising enterocolitis. Reducing mortality is an impor-
tant goal of therapy but it is essential that this be achieved
without increasing long term morbidity. Post-natal
growth may be sub-optimal particularly with regard to
head circumference [2] and this can be associated with
neuro-psychological problems particularly in the very low
birth weight infant [3], and retinopathy of prematurity is
still a major problem [4].
Studies of adult intensive care patients have highlighted
the importance of blood glucose control on rates of sepsis
and survival [5]. In the study reported by Van den Berg,
where insulin was used to tightly control blood glucose a
reduction in intensive care mortality of 32% (p < 0.04), a
reduction in mean ICU stay by 22% (p = 0.005) and a
halving of the incidence of bacteraemia (p = 0.003) was
observed [6]. Studies in both diabetic and non diabetic
patients post myocardial infarction indicate that the use
of insulin has not only immediate effects with respect of
glucose control but also improves long term outcome [7].
In adults receiving parenteral nutrition insulin has been
shown to improve net leucine balance [8]. It is not always
clear from these studies whether it is the reductions in
blood glucose per se or the anabolic effects of insulin that
are important [5]. Furthermore the medical conditions
encountered in adult intensive care are not the same as
those seen in neonatal units, but nevertheless there are
some parallels that suggest that insulin could also have a
role in newborn care.
The incidence of hyperglycaemia in premature neonates
admitted to intensive care has been reported to be
between 20% and 86% [9]; those who are small for gesta-
tional age having the greater risk [9]. We have assessed
blood glucose control over the first week of life in 8 very
low birth weight babies using the MiniMed subcutaneous
sensor. In these infants receiving standard neonatal care
38% of the readings were more than 10 mmol/l and only
0.5% of the time were readings under 2.6 mmol/l. The
hyperglycaemia was particularly common on day 2 and 3
after birth. Many of these babies were given insulin treat-
ment by intravenous infusion, as is standard neonatal
practice, when blood glucose levels were higher than10
mmol/l. Hyperglycaemia can lead to significant osmotic
diuresis and hence electrolyte imbalance and has been
associated with increased risk of intraventricular haemor-
rhage. Uncontrolled hyperglycaemia has also been associ-
ated with increased episodes of sepsis in post surgical and
burns patients [10-13]. The premature neonate is rela-
tively immunocompromised and with immature skin and
renal function is at increased risk of infection and prob-
lems with fluid and electrolyte balance. There is increasing
data documenting the association of hyperglycemia in the
neonatal population with increased morbidity and mor-
tality [14-17]. Current neonatal practice of intermittent
insulin treatment is only partially effective at controlling
hyperglycaemia in the infants who require intensive care.
The reason for these prolonged periods of hyperglycaemia
is not clear. During fetal life, insulin secretion is largely
determined by glucose flux across the placenta and blood
samples taken from foetuses at cordocentesis demon-
strated an exponential increase in fetal plasma insulin
with increasing gestation [18]. Lower plasma glucose and
insulin as well as higher glucose insulin ratios have been
shown in growth retarded foetuses compared to those
who are appropriately grown [18]. At birth, the disruption
of placental supply of nutrients leads to a period of catab-
olism with weight loss being maximal two to three days
after birth, birth weight not being recovered often until
the age of 7 days. Insulin levels are low during this period
only increasing with the establishment of oral feeds and
the coupling of insulin secretion to meal-related nutrient
and hormonal signals [19-21]. Blood glucose levels dur-
ing this period of catabolism are maintained by glucone-
ogenesis and glycolysis driven by catecholamines, growth
hormone and cortisol. In a setting of continuing limited
substrate availability, these hormones may also play a role
by reducing insulin sensitivity, increasing lipolysis, and
hence diverting glucose utilisation from muscles to the
brain, protecting the fetal brain from the risk of hypogly-
caemia [22,23].
In the very low birth weight infant, the period of neonatal
catabolism may be much more prolonged, as it may not
be possible to initiate oral feeding and thus induce nor-BMC Pediatrics 2007, 7:29 http://www.biomedcentral.com/1471-2431/7/29
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mal insulin secretion. As a consequence, birth weight is
often not regained for several weeks. The very high blood
glucose levels seen on day 3 or 4 may reflect insulin resist-
ance secondary to high levels of growth hormone and the
stress related hormones catecholamines and cortisol. They
could also reflect relative insulin deficiency and a failure
to compensate for any increasing insulin resistance. Fetal
growth restriction may be associated with impaired pan-
creatic development and a reduced β-cell mass [24-27]
although intravenous alimentation is often started soon
after birth in these infants, enteral feeding and normal β
cell function may not be achieved for several weeks.
Although insulin therapy is used intermittently on the
neonatal unit, there are few studies which have formally
assessed its benefits [28-34]. These studies have been
small and some have compared the use of insulin with
reduction in glucose infusion. One study in premature
infants using continuous insulin infusions to control
hyperglycaemia showed better glucose tolerance with
improved weight gain combined with a reduced incidence
of sepsis [28]. The use of stable isotopes has demonstrated
a role for insulin infusions in reducing proteolysis in the
low birth weight infants [31]. Thus potentially, insulin
could limit proteolysis and improve weight gain and
growth.
In a recent pilot study, we demonstrated that early contin-
uous insulin infusion effectively controlled blood glucose
levels over the first week of life and prevented the high
blood sugars seen on day 2 or 3 in infants given standard
intermittent insulin therapy. These data indicate that insu-
lin replacement early from birth may prevent some of the
catabolism and insulin resistance normally observed in
the pre-term infant. Thus insulin replacement in the new-
born could reverse the risk associated with high blood
sugar: it could improve anabolism and weight gain, and
theoretically by reducing hyperglycaemia, reduce risk of
sepsis. Insulin therapy in the newborn could also have
more far reaching benefits. Levels of insulin like growth
factor 1 (IGF-1) and the inhibitory IGF binding protein
IGFBP-1 are regulated by insulin in the newborn [35-37].
IGF-I has an important role in fetal and postnatal brain
growth [38,39]. Furthermore, low IGF-1 levels [40-42]
and hyperglycemia [43] have been implicated in the
pathogenesis of retinopathy of prematurity. Thus theoret-
ically, improved insulin delivery and restoration of IGF-I
levels could have important implications for the long
term outcome as well as the short term survival of very low
birth weight babies.
Hypothesis
We propose that relative insulin deficiency in the very low
birth weight baby leads to catabolism, insulin resistance
and hyperglycaemia during the first week of life. High
blood glucose levels may lead to osmotic diuresis and
increase the risk of sepsis. Insulin deficiency may contrib-
ute to slow weight gain and impaired IGF-I generation
which could have implications for risk of retinopathy,
brain growth and later neurodevelopmental outcomes.
We hypothesise that early intervention with continuous
insulin replacement will prevent catabolism and improve
glucose control, and could reduce neonatal morbidity and
mortality.
Aims of the study
To carry out a multi-centre, randomised controlled study
of early insulin replacement in very low birth weight
infants (VLBW < 1500 g). 500 children will be ran-
domised to receive either a continuous infusion of insulin
(0.05 u/kg/hr) from within 24 hours of birth and for the
first 7 days of life, or to act as controls and receive stand-
ard neonatal care.
Objectives
Primary
To investigate whether an early fixed dose insulin infu-
sion, combined with variable dextrose support to main-
tain normoglycaemia, will reduce mortality on or before
expected date of delivery in the very low birth weight
neonate.
Secondary
(i) incidence of sepsis in the first 2 weeks of life; (ii)
growth at 28 days; (iii) incidence of necrotizing enterocol-
itis (iv) severity of retinopathy of prematurity; (v) inci-
dence of intracranial haemorrhage (vi) incidence of
chronic lung disease (vii) mortality before 28 days of age
(viii) total number of days in neonatal intensive care prior
to discharge home
Efficacy outcomes
(i) Blood glucose control over the first week of life as
assessed by the MiniMed subcutaneous continuous glu-
cose monitor (CGMS); (ii) Effects of treatment on circu-
lating IGF-I, IGFBP-1, cytokines.
Methods/Design
Study design
The study is a multicentre randomised controlled trial. It
is based in 10 neonatal intensive care units and 500
babies will be recruited over 2 years. Very low birth weight
babies (VLBW < 1500 g) will be recruited within 24 hours
of delivery and followed until expected date of delivery
(40 weeks). They will be randomised to either treatment
with early fixed dose insulin (0.05 unit/kg/hr) with 20%
dextrose to maintain normoglycaemia, or to receive stand-
ard neonatal care. Those randomised to treatment will
receive a fixed dose of insulin combined with variable
20% dextrose support throughout the first week. Addi-BMC Pediatrics 2007, 7:29 http://www.biomedcentral.com/1471-2431/7/29
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tional insulin will be infused if blood glucose levels are
consistently above 10 mmol/l; and an infusion of 20%
dextrose will be started if blood glucose falls to <4 mmol/
l to prevent hypoglycaemia (blood glucose < 2.6 mmol/l).
Controls will receive standard neonatal care. All babies
will be monitored using a MiniMed continuous glucose
monitor for 7 completed days and have a blood sample
taken on Study days 1,3, 7 and 28. A urine sample will be
collected from all babies on Study day 7 and all babies
will have details of their clinical care recorded daily in the
first week then weekly until 4 weeks, at 36 weeks corrected
age, at expected date of delivery (40 weeks) and at dis-
charge home.
Study population
Infant Selection
Infants must fulfill all inclusion criteria – birth weight <
1500 g, requiring intensive care and in whom it is consid-
ered appropriate to continue intensive care, less than 24
hours of age, and written informed parental consent.
Infants must not have any of the following exclusion cri-
teria: maternal diabetes including gestational diabetes,
babies where the appropriateness of continuing intensive
care is being discussed, or major congenital anomalies
Inclusion in the study
If all the inclusion and exclusion criteria are met the
patient will be included in the study and allocated a
sequential patient number. The randomisation will be
stratified by centre, by birth weight (<1000 g, 1000–1500
g), and by gestational age (<25 weeks and ≥25 weeks). A
24 hour internet based randomisation programme will be
used which requires user name and is password secure.
Treatment with insulin will begin as soon after birth as is
possible following randomisation. Patient data will be
analysed on the basis of intention to treat. Consent will be
taken by a health care professional who has a good work-
ing knowledge of the aims and practicalities of the study.
Parents will be given a written information leaflet and
given the opportunity to read and discuss the information
they have been given alone. As patients need to be
recruited within 24 hours of delivery, a system of contin-
uing consent will be used over the first 3 days to ensure
that parents are happy with the decision to consent to
their baby's participation in the study.
Study medication
Study product
Insulin aspart (NovoNordisk) (pyr) for intravenous injec-
tion. Insulin will be given intravenously at a fixed rate of
0.05 u/kg/hour. It will be prepared as a standard strength
solution of 25 units/kg insulin aspart in 50 mls of 0.9%
sodium chloride to run at 0.1 ml/hr, equivalent to 0.05 u/
kg/hour. This will be combined with a variable rate 20%
dextrose infusion when required to maintain normogly-
caemia. Infusion dose will be based on the infants birth
weight and adjusted only if there is concern that the
recorded birth weight was inaccurate
Study device MiniMed CGMS (continuous glucose 
monitoring sensors)
These comprise a disposable glucose oxidase-based plati-
num electrode sensor that catalyzes interstitial glucose
generating an electrical current every 10 seconds, which is
recorded via a cable by a pager sized monitor (6 × 9 × 2
cm). The monitor records average values every 5 minutes,
giving a total of 288 readings per day. Glucose values out-
side the range 2.2–24 mmol/l (40–430 mg/dl) are
reported as <2.2 mmol/l (<40 mg/dl) or >24 mmol/l
(>430 mg/dl) respectively. Nursing and medical staff will
be instructed in the use of the monitor and asked to enter
all blood glucose (BG) measurements taken for clinical
reasons using near patient monitoring devices into the
monitor for calibration. The data cannot be viewed in real
time and therefore cannot impact on clinical care.
A. Babies randomised to insulin treatment
As is usual practice initial management will involve
obtaining intravenous access, measuring blood glucose
and initiating a dextrose infusion.
Study babies will in addition require: i) Insertion of a Min-
iMed  sensor (subcutaneous insertion in the thigh). ii)
Preparation of fixed dose insulin infusion iii) Preparation of
a separate 20% dextrose infusion, for use if the BG should
fall to <4.0 mmol/l to prevent hypoglycaemia.
i) Insertion of a MiniMed sensor (subcutaneous insertion in the thigh)
The sensor will be inserted subcutaneously in the thigh. It
will be secured in place with a clear occlusive dressing. The
sensor will be sited in the lateral aspect of the thigh by a
member of the study team who has been appropriately
trained. The sensor will be sited using aseptic technique.
The legs will be examined to ensure an area of unbroken
skin over the lateral aspect of the thigh. The skin will be
gently cleaned with damp sterile gauze and allowed to
dry. If the skin is very friable then a fine spray of cavilon
will be applied to form a barrier. Any adhesive will be
trimmed to ensure minimal contact with the skin but
allowing for secure attachment. The individual inserting
the sensor will document clearly the time and site of sen-
sor insertion and condition of the site. All BG levels will
be entered into the MiniMed Sensor to allow for calibra-
tion. These will be taken as frequently as clinically indi-
cated but a minimum of 4 readings (approximately 6
hourly) must be entered every day. These will be entered
within 5 minutes, as the monitor will record subcutane-
ous readings every 5 minutes. If there are problems with
dislodgement of the sensor it can be replaced on up to two
occasions. The sensor should be left in situ for 12 hoursBMC Pediatrics 2007, 7:29 http://www.biomedcentral.com/1471-2431/7/29
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after completion of the insulin infusion and should there-
fore be removed at midday on Day 8.
ii) Fixed Dose Insulin Infusion
Treatment: 25 units/kg insulin (aspart) in 50 mls of 0.9% (or
0.45%) sodium chloride to run at 0.1 ml/hr equivalent to 0.05
u/kg/hour. The insulin solution should be prepared in a 50
ml volume to allow a minimum of 20 mls of the solution
to be flushed through the connection tubing. This is to
reduce the adsorption of further insulin to the plastic tub-
ing during infusion.
iii) 20% dextrose
All babies receiving insulin will have a 20% dextrose infu-
sion prepared for infusion if the blood glucose levels fall
<4.0 mmol/to prevent hypoglycaemia. Calculation of the
dose of insulin will be based on the baby's birth weight
and only changed if this is felt in retrospect to be inaccu-
rate.
Initiating treatment
If the blood glucose level is >4.0 mmol/l and the baby is
receiving a minimum glucose infusion of 4 mg/kg/min
(60 ml/kg/d of 10% dextrose) then the fixed dose insulin
infusion regimen will be started. If the blood glucose is
<4.0 mmol/l then 20% dextrose will be infused and blood
glucose rechecked within one hour, repeatedly increasing
20% dextrose and checking BG hourly until BG is >4.0
mmol/l. Only when the BG is >4.0 mmol/l will the fixed
dose insulin infusion be started. Once the insulin infusion
has started the BG will be checked hourly until stable and
then 2 hourly increasing to a time interval of 4 hours. If a
baby is stable the time interval may be increased to a max-
imum of 6 hours under the guidance of the Principal
Investigator. The fixed dose insulin infusion will start
within 24 hours of delivery and will run for seven com-
pleted days. The fixed dose insulin infusion will be
infused via the same line that the baby is receiving its
main source of dextrose/parenteral nutrition. This will
ensure that if there is a break in the delivery of the main
source of dextrose to a baby that there will also be a simul-
taneous break in the infusion of insulin.
The fixed dose insulin infusion will be maintained but any
decisions regarding a baby's maintenance glucose infu-
sions and fluid requirements will be taken by the medical
team caring for the baby. If there are any clinical changes
in the rate of glucose being infused or a clinical insulin
infusion is started then a blood glucose will be rechecked
hourly until stable.
Maintaining 'Normoglycaemia' (BG 4–8 mmol/l) (Figure 1)
Aim to maintain blood glucose 4–8 mmol/l using the
infusion algorithm shown in Figure 1.
Hyperglycaemia
If blood glucose levels rise (>10.0 mmol/l on two occa-
sions) and there is no additional 20% dextrose being
infused treatment with insulin should be started to main-
tain normoglycaemia (BG 4–8 mmol/l).
Hypoglycaemia
If the blood glucose level falls <4.0 mmol/l, intravenous
lines should be reviewed and additional 20% dextrose
infused to avoid hypoglycaemia – starting at 1 ml/kg/hour
extra (see Figure 1). A review should be made of the
amount of dextrose being received and the additional
20% dextrose infusion that has been prepared should be
titrated to prevent hypoglycaemia. Repeated BG measure-
ments should be taken hourly repeatedly increasing the
20% dextrose until the value is stable and >4.0 mmol/l.
This should prevent BG levels falling to <2.6 mmol/l.
However if BG < 2.6 mmol/l then the insulin infusion
should be stopped, all lines checked to ensure the baby is
receiving the dextrose prescribed and additional 20% dex-
trose infused. A repeat BG should be taken after 60 min-
utes, and hourly with the 20% dextrose repeatedly
increased to maintain the BG 4.0–8 mmol/l. Close liaison
with the medical and nursing staff is critical to make sure
they understand the treatment algorithm and that the
study is aiming to control the BG between 4–8 mmol/l.
They must be aware of the importance of taking regular
and frequent BG measurements to ensure euglycaemia
and that 20% dextrose should be started if a BG level is
recorded that is <4.0 mmol/l.
Stopping Treatment
After the baby has received 7 days of insulin the infusion
should be stopped at midnight on Study Day 7. If the
baby has additional 20% dextrose running as well as the
insulin then the insulin should be stopped first and the
20% dextrose weaned of over a period of several hours. In
all cases the blood glucose should be monitored closely
after stopping the insulin to ensure the baby does not
become hypoglycaemic or hyperglycaemic. The Minimed
sensor should be left in situ for 12 hours after stopping the
insulin and be removed at midday on Study Day 8. Appro-
priate clinical management should be taken by the clini-
cians responsible for the baby's care.
B. Babies randomised to control arm
As is usual practice initial management will involve
obtaining intravenous access, measuring blood glucose
and initiating a dextrose infusion.
Study control babies will in addition require
i) Insertion of a MiniMed sensor (subcutaneous insertion
in the thigh, as described above).BMC Pediatrics 2007, 7:29 http://www.biomedcentral.com/1471-2431/7/29
Page 6 of 10
(page number not for citation purposes)
ii) Blood Glucose control as per standard clinical protocol
Blood glucose control
These babies will receive standard clinical care.
Therefore if BG:
<2.6 mmol/l standard unit management of hypoglycae-
mia
>10 mmol/l if 2 or more readings are >10 mmol/l con-
sider addition of insulin infusion
Once BG has fallen to <10 mmol/l then any insulin infu-
sions should be stopped.
Measurement of outcomes
Primary outcomes
Death on or before expected date of delivery (taken as
date considered the most accurate estimate of delivery
date).
Secondary outcomes
i. Episodes of sepsis in the first 2 weeks: 
a) Culture positive systemic infection will be defined as
microbiologically positive cultures of blood, cerebrospi-
nal fluid or suprapubic aspirate of urine plus clinical signs
of sepsis.
Guidance for maintaining blood glucose using fixed dose insulin and variable rate 20% dextrose Figure 1
Guidance for maintaining blood glucose using fixed dose insulin and variable rate 20% dextrose.BMC Pediatrics 2007, 7:29 http://www.biomedcentral.com/1471-2431/7/29
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b) Culture negative infection will be defined as clinical
signs suggestive of sepsis and considered to warrant >48
hours of antibiotics but with negative cultures.
ii. Growth: All babies will have measurements of weight,
length and head circumference at birth and every seven
completed days after recruitment until EDD. Growth will
be assessed as change in weight, length and head circum-
ference standard deviation score (SDS) from birth to 28
days using conditional charts.
iii. Incidence of necrotizing enterocolitis: defined as radio-
logical evidence of necrotizing entercolitis assessed by
consultant radiologist.
iv. Retinopathy of prematurity: All these babies will be rou-
tinely screened, for retinopathy of prematurity and will be
graded using the internationally recognised grading sys-
tem [44,45]. Infants will be classified by the most severe
degree of retinopathy.
v. Incidence of intracranial haemorrhage: defined as cra-
nial ultrasound evidence as assessed by Consultant
Neonatologist.
vi. Chronic lung disease: defined as respiratory support or
oxygen dependency at 36 weeks corrected gestational age
[46].
vii. Death within and including the first 28 days after deliv-
ery
viii. Days of neonatal intensive care: As defined by BAPM
2002[47].
Efficacy
i. Percent of time normoglycaemic: All babies will have a
continuous glucose sensor in situ for the 7 completed
days. Sensors will be inserted within 24 hours of birth and
left in situ for 7 days from the time of insertion. The sen-
sors will be removed 12 hours after the insulin infusion
has stopped. This will take a measure of interstitial glucose
every 5 minutes and will give an assessment of glucose
control throughout the first week. The percent of time
spent with blood glucose <2.6 mmol/l, 2.6–10.0 mmol/l,
>10 mmol/l and <4.0, 4.0–8.0 mmol/l, >8.0 mmol/l will
be measured.
ii. IGF-I and IGFBP-1: measured in blood taken on Study
Days 1, 3, 7 and 28.
iii) cytokines: measured in blood taken on Study Days 1,
3, 7 and 28.
iv) protein catabolism: measured by urinary 3-methylhis-
tidine/creatinine ratio on Study day 7.
Continuation of insulin treatment after 7 days
If a baby becomes hyperglycaemic after the study dose of
insulin has been stopped it will be a decision of the doc-
tors responsible for the patients medical care whether
insulin should be restarted, what preparation will be used
and what dose administered.
Concomitant therapy
All other therapy considered necessary for the patients
welfare may be given at the discretion of the medical staff
in charge of the infant's medical care.
Withdrawal from treatment
A patient will be withdrawn from the study if in the opin-
ion of the Investigator it is medically necessary or if it is
the parents wish for a child to be withdrawn. The reason
for withdrawal should be clearly documented in the Case
Report Form and reported to the co-ordinating centre
within 24 hours.
Follow up
Contact details and hospital identifiers for all patients in
all centres will also be collected so that future follow up
will be possible. If there are effects on short term growth
it will be important to review growth, body composition
and insulin resistance in later childhood, as well as neu-
rodevelopmental outcome. As is current practice in early
neonatal deaths, in any baby who dies during the study
period, the parents would be approached for consent to a
post mortem being performed.
Statistics
Intention to treat analyses will be performed comparing
the outcome of all infants allocated to early insulin treat-
ment compared to those allocated placebo, regardless of
how complete treatment was. Statistical analyses will use
standard methods to calculate the event rates, time-to-
event rates, relative risks, and numbers needed to treat for
each outcome in the treatment compared with placebo
group, along with 95% confidence intervals. Where
appropriate χ2, Fisher's exact or log rank tests of signifi-
cance will be performed and presented with p-values.
The primary outcome will be modelled with logistic
regression in order to evaluate a 95% confidence interval
for odds ratio according to treatment group adjusted for
key prognostic variables, including if significant, geo-
graphic centre. No formal interim analyses are intended
although the trial's Data Monitoring Committee (DMC)
will meet regularly, have access to unblinded data and
would recommend early termination to the Trial Steering
Committee ifjudged appropriate based on ethical, safetyBMC Pediatrics 2007, 7:29 http://www.biomedcentral.com/1471-2431/7/29
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or efficacy considerations. Time to event analyses strati-
fied by category of birthweight, using Kaplan-Meier sur-
vival analyses and stratified logrank tests will be used to
assist DMC decision-making. For the secondary out-
comes, modelling with either multiple regression (for
continuous variables) or logistic regression (for binary
variables) will be employed, adjusting for the same base-
line covariates as the primary analysis. If individual terms
in models are non-significant at level 0.05, then simpler
models may be presented instead.
A secondary analysis will be on an "as treated" basis,
defining treatment exposure as at least 4 days without
interruptions of more than 1 hour.
Power calculation
Sample size is based on the primary outcome variable of
mortality. This is based on statistical power analyses for
mortality of 20% by EDD. To predict an absolute differ-
ence of 10% with 80% power at the 5% level of signifi-
cance we would need 428 patients. Non-compliance is
not likely to be a problem, although withdrawal from
treatment may be 5–10%. Thus we aim to recruit 500
patients. Each unit has an admission rate of approxi-
mately 100 very low birth weight babies per year. Due to
the confined period of recruitment being within 24 hours
of delivery we predict 50% availability for recruitment
(some babies will be transferred in after delivery). Cou-
pled with an estimated 60% rate of consent we predict we
would recruit 500 infants over a 2 year period with a real-
istic safety margin. For the primary outcome measure of
mortality by EDD loss to follow up should be negligible.
Ethical and regulatory issues
Patient information and consent
Parents will be given full verbal and written information
regarding the objective and procedures of the study and
the possible risks involved. If possible parents will be
approached prior to delivery to allow time for considering
study details prior to giving assent. However all parents
would be asked to confirm informed consent in writing
after a baby's birth. As patients need to be recruited within
24 hours of delivery, a system of continuing consent will
be used over the first 3 days to ensure that parents are
happy with the decision to consent to their baby's partici-
pation in the study.
Regulatory bodies
EUDRACT Number: 2004-002170-34
MHRA: DDX granted 21/4/04 became a CTA 1/4/04
UK Sponsor Cambridge University Hospital NHS Founda-
tion Trust
Study timetable
The study started in Cambridge in January 2005 following
confirmation of final protocol approval by ethics commit-
tees and MHRA regulatory approval. New study centres
were then taken on over the subsequent 12 months and
recruitment is currently on target to be completed by
December 2007. All laboratory analyses will be com-
pleted within 6 months of the last patient recruited.
Discussion
This study is based on the hypothesis that early interven-
tion with insulin replacement prevents catabolism and
the hyperglycaemia seen during the first week of life, in
the VLBW preterm infant. The strategy is not simply that
used in adult intensive care to actively titrate insulin in
subjects with hyperglycaemia, although the adult out-
come data particularly with respect to reductions in sepsis,
with tight glycemic control, may have interesting paral-
lels. Our approach, to administer continuous insulin with
glucose cover also provides additional safety compared to
sliding scales of insulin generally used in this population,
and also highlights the differences with adult ICU proto-
cols. Although mortality and morbidity rates are much
lower in infants 1–1.5 kg compared to those <1 Kg it was
felt that these infants may well benefit from any long term
effect on growth and/or reduction in the incidence of
retinopathy and therefore they have been included in the
protocol.
Summary
Very low birth weight infants requiring intensive care have
relative insulin deficiency often leading to hyperglycae-
mia during the first week of life which has been associated
with increased mortality and morbidity. The physiologi-
cal influences on insulin secretion and sensitivity, and the
potential importance of interventions to improve glucose
control at this time are not well established. However the-
oretically, improved insulin delivery and restoration of
IGF-I levels could have important implications for short
term survival as well as the long term outcomes of these
VLBW babies. This is a multi-centre, randomised control-
led trial of early insulin replacement in VLBW babies.
Babies will be randomised to receive a continuous insulin
infusion (0.05 units/kg/h) with 20% dextrose support or
to receive standard neonatal care for the first 7 days of life.
The primary end point will be mortality on or before
expected date of delivery, secondary end points will be
markers of morbidity and include episodes of sepsis,
severity of retinopathy, chronic lung disease and growth.
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